Table 1 Ranking of HTA Domains and assessment elements
Element ID | Topic/Issue | Median (IQR) | No of responses (%) |
|---|---|---|---|
Health problem and current use of the technology (CUR) | 5 (4,5) | 24 | |
Target population | |||
A0007 | What is the target population in this assessment? | 5 (4,5) | 24 |
A0023 | How many people belong to this target population | 5 (3.75, 5) | 24 |
Target condition | |||
A0002 | What is the health condition | 5 (4,5) | 24 |
A0003 | What are the known risk factors? | 5 (4,5) | 24 |
A0004 | What is the natural course of the health condition? | 4 (4,5) | 23 |
A0005 | What are the symptoms or health condition for the patient? | 4 (4,5) | 24 |
A0006 | What are the consequences of the health condition for the society? | 4.5 (4,5) | 22 |
A0009 | What aspects of the consequences are targeted by the Umbiflow? | 4 (4,5) | 23 |
Current management of the condition | |||
A0018 | What are the other typical or common alternatives to the Umbiflow? | 4 (3.5,5) | 23 |
A0024 | How is the health condition currently diagnosed according to published guidelines and in practice? | 4 (4,5) | 24 |
A0025 | How is the health condition currently managed according to published guidelines and in practice? | 4 (4,5) | 24 |
Utilization | |||
A0001 | For which health conditions and populations, and for what purposes is the technology used? | 4 (3,5) | 24 |
A0011 | How much are the technologies utilized? | 4 (3,5) | 24 |
F0001 | Is Umbiflow a new, innovative mode of care, an add-on to, or modification of a standard mode of care, or a replacement of a standard mode of care? | 4 (3,5) | 24 |
Description and technical characteristics of technology (TEC) | 4 (3,5) | 24 | |
Safety (SAF) | 5 (4,5) | 24 | |
Patient safety | |||
C0006 | What are the consequences of false positive, false negative and incidental findings generated by using the technology from the viewpoint of patient safety? | 4 (3,5) | 24 |
Clinical effectiveness (EFF) | 4 (4,5) | 23 (95.8) | |
Mortality | |||
D0001 | What is the expected beneficial effect of intervention on mortality? | 4 (4,5) | 24 |
Morbidity | |||
D0005 | How does using Umbiflow affect findings of the health condition? | 4 (4,5) | 24 |
D1004 | What are the requirements for accuracy in the context where the technology will be used? | 4 (3,5) | 24 |
Change-in-management | |||
D0020 | Does use of the test lead to improved detection of the condition? | 4 (4,5) | 24 |
D0010 | How does the technology modify the need for hospitalisation? | 4 (3,5) | 24 |
Benefit-harm balance | |||
D0029 | What are the overall benefits and harms of the technology in health outcomes? | 4 (3,5) | 24 |
Costs and Economic aspect | 4 (3.4,5) | 24 | |
Process-related costs | |||
G0006 | What are the costs of processes related to acquisition and setting up new technology? | 4 (3,5) | 23 |
G0007 | What are the likely budget impacts of implementing the technology? | 4 (3,5) | 23 |
Ethical aspect | 4 (4,5) | 24 | |
Autonomy | |||
F0006 | Is there a need for any specific interventions or supportive actions concerning information in order to respect patient autonomy when the technology is used? | 4 (3.5,5) | 23 |
F0007 | Does the implementation or withdrawal of the technology challenge or change professional values, ethics or traditional roles? | 4 (3,4.5) | 23 |
Legislation | |||
F0014 | Does the implementation or use of the technology affect the realisation of basic human rights? | 4 (3,5) | 23 |
Organizational aspect | 4 (3,5) | 24 | |
Health delivery process | |||
G0001 | How does the technology affect the current work processes? | 4 (3,5) | 24 |
G0100 | What kind of patient/participant flow is associated with the new technology? | 4 (3,5) | 24 |
G0002 | What kind of involvement has to be mobilised for patients/participants and important others and/or caregivers? | 4 (3,5) | 21 |
G0003 | What kind of process ensures proper education and training of staff? | 4 (3,5) | 23 |
Management | |||
G0008 | What management problems and opportunities are attached to the technology? | 4 (3,5) | 24 |
Patient and social aspect | 4 (4,5) | 23 (95.8) | |
Patient’s perspectives | |||
H0100 | What expectations and wishes do patients have with regard to the technology and what do they expect to gain from the technology? | 4 (3,5) | 24 |
Communication aspects | |||
H0202 | How are treatment choices explained to patients? | 4 (3,5) | 24 |
Legal aspect | 4 (3.5,5) | 23 (95.8) | |
Autonomy of the patient | |||
I0034 | Who is allowed to give consent for minors and incompetent persons? | 4 (3,5) | 24 |
Privacy of the patient | |||
I0009 | What do laws/binding rules require with regard to appropriate measures for securing patient data and how should this be addressed when implementing the technology? | 4 (3.75,4.25) | 24 |